A Randomized, Controlled, Masked, Multi-center Study Evaluating the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501 Compared to an Untreated Control Group in Male Participants with X-linked Retinitis Pigmentosa (VISTA)

Research summary

This study is a randomized, controlled, dose-masked, multi-center study evaluating and comparing 2 doses of AGTC-501 to an untreated control group. A single subretinal injection of AGTC-501 (200 μL containing either 6.8 x 1011 vg per eye [high dose] or 3.7 x 1011 vg per eye [low dose]) will be administered to participants in 2 treatment groups (n = ~25 in each group). Once the primary analysis has been completed and the database has been frozen, participants in the untreated control group may be offered treatment with the high dose of AGTC-501 in their fellow eye, if eligible.

Principal Investigator

Dr Jasmina Cehajic- Kapetanovic

Contact us

Email: ERGO@ouh.nhs.uk

IRAS number

1009737